Progress in Medical Physics (한국의학물리학회지:의학물리)

Korean Society of Medical Physics (한국의학물리학회)
권호 표지
DOI QR코드

DOI QR Code

Feasibility and Efficacy of Adaptive Intensity Modulated Radiotherapy Planning according to Tumor Volume Change in Early Stage Non-small Cell Lung Cancer with Stereotactic Body Radiotherapy

폐암의 정위적체부방사선치료에서 육안적종양체적 변화에 따른 적응방사선치료의 효용성 및 가능성 연구

  • Park, Jae Won (Department of Radiation Oncology, Yeungnam University Medical Center) ;
  • Kang, Min Kyu (Department of Radiation Oncology, Yeungnam University Medical Center) ;
  • Yea, Ji Woon (Department of Radiation Oncology, Yeungnam University Medical Center)
  • 박재원 (영남대학교병원 방사선종양학과) ;
  • 강민규 (영남대학교병원 방사선종양학과) ;
  • 예지원 (영남대학교병원 방사선종양학과)
  • Received : 2015.05.05
  • Accepted : 2015.06.15
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study is to evaluate efficacy and feasibility of adaptive radiotherapy according to tumor volume change (TVC) in early stage non-small cell lung cancer (NSCLC) using stereotactic body radiotherapy (SBRT). Twenty-two lesions previously treated with SBRT were selected. SBRT was usually performed with a total dose of 48 Gy or 60 Gy in four fractions with an interval of three to four days between treatments. For evaluation of TVC, gross tumor volume (GTV) was contoured on each cone-beam computed tomography (CBCT) image used for image guidance. Intensity modulated radiotherapy (IMRT) planning was performed in the first CBCT (CBCT1) using a baseline plan. For ART planning (ART), re-optimization was performed at $2^{nd}$, $3^{rd}$, and $4^{th}$ CBCTs (CBCT2, CBCT3, and CBCT4) using the same angle and constraint used for the baseline plan. The ART plan was compared with the non-ART plan, which generated copying of the baseline plan to other CBCTs. Average GTV volume was 10.7 cc. Average TVC was -1.5%, 7.3%, and -25.1% in CBCT2, CBCT3, and CBCT4 and the TVC after CBCT3 was significant (p<0.05). However, the nine lesions were increased GTV in CBCT2. In the ART plan, $V_{20\;Gy}$, $D_{1500\;cc}$, and $D_{1000\;cc}$ of lung were significantly decreased (p<0.05), and $V_{30\;Gy}$ and $V_{32\;Gy}$ of the chest wall were also decreased (p<0.05). While D min of planning target volume (PTV) decreased by 8.3% in the non-ART plan of CBCT2 compared with the baseline plan in lesions with increased tumor size (p=0.021), PTV coverage was not compromised in the ART plan. Based on this result, use of the ART plan may improve target coverage and OAR saving. Thus ART using CBCT should be considered in early stage NSCLC with SBRT.

이 연구는 조기 폐암의 정위방사선치료에서 육안적종양체적(Gross tumor volume, GTV) 변화에 따른 적응방사선치료(ART)의 효과 및 가능성을 보기 위해 시행되었다. 영남대학교 의료원에서 정위방사선치료를 시행한 22개의 종양을 대상으로 연구를 진행하였다. 정위방사선치료는 2주에 걸쳐 48 혹은 60 Gy를 4회에 나누어 조사하는 방법으로 시행되었다. 종양체적 변화를 측정하기 위해 매 콘빔시티마다 육안적종양체적에 대한 윤곽선 그리기를 시행하였다. 그 다음 첫 번째 콘빔시티에 기준 치료계획으로 사용할 세기조절방사선치료 계획을 시행하였다. 적응방사선치료 계획을 하기 위해, 2, 3, 4번째 콘빔시티에 기준 치료계획과 동일한 빔 각도와 제약을 적용하여 각각 재 최적화 과정을 진행하였다. 이후 적응방사선치료 계획은 기준치료계획을 각각의 콘빔시티에 복사하여 생성한 비적응방사선치료 계획과 비교되었다. 평균 육안적종양체적은 10.7 cc였다. 평균 종양체적 변화는 두 번째, 세 번째, 네 번째 콘빔시티에서 각각 -1.5%, 7.3%, 25.1%였으며 세 번째 이후 변화는 통계적으로 유의하였다(p<0.05). 하지만 두 번째 콘빔시티에서는 9개의 종양 체적이 증가하였다. 적응방사선치료 계획을 시행하였을 때, 폐에서 $V_{20\;Gy}$, $D_{1500\;cc}$, $D_{1000\;cc}$가 유의하게 감소하였으며, 흉벽에 대한 $V_{30\;Gy}$와 $V_{32\;Gy}$ 역시 유의하게 감소하였다(p<0.05). 두 번째 콘빔시티의 종양체적이 증가한 환자들에서, 기준치료 계획에 비해 적응치료방사선치료 계획을 시행하지 않았을 때, 계획용 표적체적에 대한 선량 범위 변수 중 $D_{min}$은 8.3% 감소한 반면 (p=0.021), 적응방사선치료계획을 시행한 경우에는 차이가 없었다. 이러한 결과를 보았을 때, 적응방사선치료 계획을 함으로서 표적 선량 커버는 개선시키면서 손상위험장기에 대한 선량을 감소시킬 수 있을 것이다. 그러므로, 콘빔시티를 이용한 적응방사선치료 방법은 조기 폐암의 정위방사선치료에서 고려되어야 하겠다.

Keywords

References

  1. Ricardi U, Frezza G, Filippi AR, et al. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung cancer 84(3):248-53 (2014). https://doi.org/10.1016/j.lungcan.2014.02.015
  2. Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung cancer 66(1):89-93 (2009). https://doi.org/10.1016/j.lungcan.2008.12.016
  3. Matsuo Y, Chen F, Hamaji M, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. European journal of cancer 50(17):2932-8 (2014). https://doi.org/10.1016/j.ejca.2014.09.006
  4. Port JL, Parashar B, Osakwe N, et al. A propensity matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer. The Annals of thoracic surgery 98(4):1152-9 (2014). https://doi.org/10.1016/j.athoracsur.2014.04.128
  5. Zhang B, Zhu F, Ma X, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 112(2):250-5 (2014). https://doi.org/10.1016/j.radonc.2014.08.031
  6. Kestin L, Grills I, Guckenberger M, et al. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 110(3):499-504 (2014). https://doi.org/10.1016/j.radonc.2014.02.002
  7. Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. International journal of radiation oncology, biology, physics 91(2):344-50 (2015). https://doi.org/10.1016/j.ijrobp.2014.10.002
  8. Matsuo Y, Shibuya K, Nakamura M, et al. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. International journal of radiation oncology, biology, physics 83(4):e545-9 (2012). https://doi.org/10.1016/j.ijrobp.2012.01.018
  9. Asai K, Shioyama Y, Nakamura K, et al. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship. International journal of radiation oncology, biology, physics 84(3):768-73 (2012). https://doi.org/10.1016/j.ijrobp.2012.01.027
  10. Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. International journal of radiation oncology, biology, physics 76(3):796-801 (2010). https://doi.org/10.1016/j.ijrobp.2009.02.027
  11. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24(30):4833-9 (2006). https://doi.org/10.1200/JCO.2006.07.5937
  12. Erridge SC, Seppenwoolde Y, Muller SH, et al. Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 66(1):75-85 (2003). https://doi.org/10.1016/S0167-8140(02)00287-6
  13. Siker ML, Tome WA, Mehta MP. Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? International journal of radiation oncology, biology, physics 66(1):135-41 (2006). https://doi.org/10.1016/j.ijrobp.2006.03.064
  14. Bhatt AD, El-Ghamry MN, Dunlap NE, et al. Tumor volume change with stereotactic body radiotherapy (SBRT) for early-stage lung cancer: evaluating the potential for adaptive SBRT. American journal of clinical oncology 38(1):41-6 (2015). https://doi.org/10.1097/COC.0b013e318287bd7f
  15. Gunter T, Ali I, Matthiesen C, et al. Gross tumour volume variations in primary non-small-cell lung cancer during the course of treatment with stereotactic body radiation therapy. Journal of medical imaging and radiation oncology 58(3):384-91 (2014). https://doi.org/10.1111/1754-9485.12168
  16. Saito AI, Olivier KR, Li JG, et al. Lung tumor motion change during stereotactic body radiotherapy (SBRT): an evaluation using MRI. Journal of applied clinical medical physics / American College of Medical Physics, 15(3):4434 (2014).
  17. Tatekawa K, Iwata H, Kawaguchi T, et al. Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy. Radiation oncology 9:8 (2014). https://doi.org/10.1186/1748-717X-9-8
  18. Yi BS, Perks J, Houston R, et al. Changes in position and volume of lung cancer target volumes during stereotactic body radiotherapy (SBRT): is image guidance necessary? Technology in cancer research & treatment 10(5):495-504 (2011). https://doi.org/10.7785/tcrt.2012.500226
  19. Feng M, Kong FM, Gross M, et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. International journal of radiation oncology, biology, physics 73(4):1228-34 (2009). https://doi.org/10.1016/j.ijrobp.2008.10.054
  20. Bral S, Duchateau M, De Ridder M, et al. Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 91(3):438-42 (2009). https://doi.org/10.1016/j.radonc.2009.03.015
  21. Britton KR, Starkschall G, Tucker SL, et al. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. International journal of radiation oncology, biology, physics 68(4):1036-46 (2007). https://doi.org/10.1016/j.ijrobp.2007.01.021
  22. Kupelian PA, Ramsey C, Meeks SL, et al. Serial megavoltage CT imaging during external beam radiotherapy for non-small- cell lung cancer: observations on tumor regression during treatment. International journal of radiation oncology, biology, physics 63(4):1024-8 (2005). https://doi.org/10.1016/j.ijrobp.2005.04.046
  23. Westhoff PG, de Graeff A, Geerling JI, Reyners AK, van der Linden YM. Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: a multicenter double-blind placebo-controlled randomized trial. BMC cancer 14:347 (2014). https://doi.org/10.1186/1471-2407-14-347
  24. Pan HY, Allen PK, Wang XS, et al. Incidence and predictive factors of pain flare after spine stereotactic body radiation therapy: secondary analysis of phase 1/2 trials. International journal of radiation oncology, biology, physics 90(4):870-6 (2014). https://doi.org/10.1016/j.ijrobp.2014.07.037
  25. Shirata Y, Jingu K, Koto M, et al. Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis. Radiation oncology 7:182 (2012). https://doi.org/10.1186/1748-717X-7-182
  26. Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. International journal of radiation oncology, biology, physics 82(1): 457-62 (2012). https://doi.org/10.1016/j.ijrobp.2010.08.056
  27. Yoo S, Yin FF. Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. International journal of radiation oncology, biology, physics 66(5):1553-61 (2006). https://doi.org/10.1016/j.ijrobp.2006.08.031
  28. Yang Y, Schreibmann E, Li T, Wang C, Xing L. Evaluation of on-board kV cone beam CT (CBCT)-based dose calculation. Physics in medicine and biology 52(3):685-705 (2007). https://doi.org/10.1088/0031-9155/52/3/011
  29. Altorjai G, Fotina I, Lutgendorf-Caucig C, et al. Cone-beam CT-based delineation of stereotactic lung targets: the influence of image modality and target size on interobserver variability. International journal of radiation oncology, biology, physics 82(2): e265-72 (2012). https://doi.org/10.1016/j.ijrobp.2011.03.042
  30. Guckenberger M, Richter A, Wilbert J, Flentje M, Partridge M. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. International journal of radiation oncology, biology, physics 81(4):e275-82 (2011). https://doi.org/10.1016/j.ijrobp.2011.01.067